Meeting
2023 ASCO Breakthrough
Serum-based parameters as distinctive predictive biomarkers in patients with hepatocellular carcinoma undergoing curative radiation therapy.
Authors
Dong-Soo Lee
College of Medicine, The Catholic University of Korea, Seoul, South Korea
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Multimodality Treatments
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 48)
DOI
10.1200/GO.2023.9.Supplement_1.48
Abstract #
48
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
The value of inflammatory markers in predicting overall survival in older adults with cancer.
First Author: Tomohiro F. Nishijima
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis.
First Author: Timothy J. Brown
Poster
2023 ASCO Annual Meeting
Application of the albumin-bilirubin (ALBI) grade as predictive marker of atezolizumab plus bevacizumab (A+B) treatment outcomes for patients with advanced hepatocellular carcinoma (HCC): Real-world retrospective analysis at Veterans Health Administration (VHA).
First Author: Munaf Alkadimi
Poster
2023 ASCO Annual Meeting
C-reactive protein as a response biomarker to immune checkpoint blockade: A meta-analysis.
First Author: Alexander B Karol